Randomized Sham-controlled Trial Investigating Efficacy of Gastric Peroral Endoscopic Myotomy in Treatment of Diabetic Gastroparesis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Changes in gastric emptying
研究概览
简要总结
The goal of this randomized sham-controlled trial is to ivestigate efficacy and safety of G-POEM in treatment of diabetic gastroparesis and explore impact of G-POEM on glucose metabolism and incretine hormones.
详细描述
Study Design The study is a single-centre double-blinded sham-controlled randomized trial. All patients have the same baseline characterization. Patients and researchers will be blinded to allocation in trial. Before randomization patients will have an additional meal test performed addressing metabolic characterization of the incretine hormones at baseline. Patients will afterwards be allocated to either the group receiving G-POEM or to the control group where a sham procedure consisting of a gastroscopy with biopsy during general anaesthesia will be done. The randomization will be carried out per-operatively. A computer-generated bloc randomization with sizes of four will be applied. The study will consist of 5 study visits, with a follow-up of 90 days after procedure. Symptoms and adverse event will be monitored 7, 30, and 90 days after intervention. During the 90-day follow-up all primary and secondary outcome will be reassessed.
G-POEM procedure is carried out in general anaesthesia in the operating theatre at the Department of Surgery, Hvidovre Hospital. Procedures will be performed by experienced surgeons from the Gastro Unit at Hvidovre Hospital,who postoperatively will have no contact with the research team or study participants. Patients will receive the same care during hospitalization.
Patients allocated to sham procedure will have 4 mucosa biopsies from antrum. All biopsies will be handled with formalin and transported to Zealand University Hospital. Here they will be formalin fixed paraffin-embedded and kept in a biobank.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Patients and researchers will be blinded to allocation in the trial.
入排标准
- 年龄范围
- 18 Years 至 85 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The ability to give signed written informed consent,
- •Patients with diabetes and gastroparesis,
- •Age >18 years,
- •Gastroparesis is diagnosed with technetium-scintigraphy,
- •Normal gastroscopy,
排除标准
- •Ongoing cancer treatment or other concurrent illness that will make the patient unable to attend the study on the discretion of the investigator,
- •Recent gastrointestinal surgery,
- •Active duodenal/gastric ulcer disease,
- •Diseases in the ventricle or previously complicated upper abdominal surgery,
- •Previous bariatric surgery,
- •Pregnancy or breastfeeding,
- •Parkinson disease,
- •Persons who, in the judgement of the investigator, may be unable to follow the protocol, Use of metoclopramide, domperidone, prucalopride, ghrelin, macrolide antibiotics (eg, azithromycin, clarithromycin, erythromycin) during study period.
- •drugs with an anti-cholinergic mechanism,
- •Use of motility slowing agents: anticholinergic agents, calcium channel blockers, TCA, GLP-1 analogs, Lithium, diphenhydramin, glucagon, dopamine agonists, progesterone, L-dopa, calcitonine, octreotide, interferon alfa, sucralsulfate,
- •botulinum toxin injections (eg, Botox®) by pyloric injection less than 4 months prior to procedure
结局指标
主要结局
Changes in gastric emptying
时间窗: 90 days after intervention
assessed by technetium scintigraphy
次要结局
- Concentration of C-peptide in pmol/L(90 days after intervention.)
- Changes in continuous glucose(90 days after intervention.)
- Incidence of Treatment-Emergent Adverse Events rated by the ASGE lexicon for adverse events(7,30 and 90 days)
- Changes in postprandial incretinhormones(90 days after intervention.)
- Changes in gastroparesis cardinal symptom index (GCSI)(7, 30 and 90 days after intervention.)
- Changes in Plasma glucose(90 days after intervention.)
研究者
Melina Svraka Hansen
Principal Investigator
Hvidovre University Hospital
